Výsledky vyhledávání

P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study

Autor: M Allez, J D Lewis, S B Hanauer, S Danese, P M Irving, C Gasink, T Hoops, J L Izanec, T Ma, E V Loftus, E J Scherl, R Panaccione, W J Sandborn, B E Sands

Publikováno v: Journal of Crohn's and Colitis. 16:i379-i380

Background Entry criteria and outcome measures of Crohn’s disease (CD) clinical trials have evolved. Patients are now required to have active inflammation on screening endoscopy, with some studies requiring moderate-severe SES-CD scores. Recent tri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fa7e758d8f8fa42764d6e5cccdf7201e
https://doi.org/10.1093/ecco-jcc/jjab232.504

Zobrazit plný text záznamu

P508 Dose adjustment in patients with moderate to severe ulcerative colitis: results from year 3 of the UNIFI maintenance study long-term extension

Autor: D S Rowbotham, E J Scherl, B E Sands, R Panaccione, L Peyrin-Biroulet, H Zhang, Y Miao, R W Leong, W Afif, R P Arasaradnam, S Danese, C Marano

Publikováno v: Journal of Crohn's and Colitis. 15:S488-S489

Background The UNIFI randomized-withdrawal maintenance study and long-term extension (LTE) evaluated the safety and efficacy of subcutaneous (SC) ustekinumab (UST) in patients with moderately to severely active ulcerative colitis (UC) who had respond

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::87ce69ef6b95d408b8ad215cd17bc869
https://doi.org/10.1093/ecco-jcc/jjab076.630

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání